Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 16/20 | 0.44 |
| ▸ | MAG | P20916 | 2/20 | 0.42 |
| ▸ | SIGLEC7 | Q9Y286 | 2/20 | 0.41 |
| ▸ | SELL | P14151 | 1/20 | 0.40 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18718049 | 0.94 | CD22 (0.46) | CD22MAGSELLSELP | |
| SCHEMBL21334206 | 0.91 | CD22 (0.47) | CD22MAGSIGLEC7SELLSELP | |
| SCHEMBL18718069 | 0.91 | CD22 (0.47) | CD22MAGSIGLEC7SELLSELP | |
| SCHEMBL18718058 | 0.91 | CD22 (0.47) | CD22MAGSIGLEC7SELLSELP | |
| SCHEMBL16407968 | 0.89 | CD22 (0.48) | CD22MAG | |
| SCHEMBL15215708 | 0.89 | CD22 (0.48) | CD22MAG | |
| SCHEMBL17853991 | 0.88 | CD22 (0.48) | CD22MAGSIGLEC7 | |
| SCHEMBL25787323 | 0.87 | CD22 (0.51) | CD22MAG | |
| SCHEMBL12061293 | 0.87 | MAG (0.52) | CD22MAGSIGLEC7SELLSELP | |
| SCHEMBL17857272 | 0.86 | MAG (0.46) | CD22MAGSIGLEC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150064240-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. | 2015-03-05 | — | — | US | disclosed |
| US-8889616-B2 | MUC1 based glycolipopeptide vaccine with adjuvant | ONCOTHYREON INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8329639-B2 | MUC1 based glycolipopeptide vaccine with adjuvant | ONCOTHYREON INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120282329-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120219617-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282329-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | MUC1, LGALS3BP, ST3GAL3 | CD22 320/4885MAG 99/4885SIGLEC7 4/4885 |
| US-20150064240-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | MUC1, LGALS3BP, ST3GAL3 | CD22 320/4885MAG 99/4885SIGLEC7 4/4885 |
| US-20120219617-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | MUC1, LGALS3BP, ST3GAL3 | CD22 320/4885MAG 99/4885SIGLEC7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.